<span item_type="fundamental" item_id="daa7e694a3c5ed377a287f8825e216c9" counter_id="ST/US/MNOV" env="prod"></span><span item_type="announcement" item_id="618164684677775361" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 409.66 K.</p><p>EPS: As of FY2025, the actual value is USD -0.24, beating the estimate of USD -0.38.</p><p>EBIT: As of FY2025, the actual value is USD -14.59 M.</p><p></p><h4>Net Sales</h4><p>Net sales for MediciNova, Inc. were $409,657 for the fiscal year ended December 31, 2025, with no net sales recorded in the prior fiscal year. This revenue in 2025 was recognized under an agreement with Mayo Foundation for Medical Education and Research <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Operating Loss</h4><p>Operating loss for the fiscal year ended December 31, 2025, was -$13,283,002, compared to -$12,675,331 for the fiscal year ended December 31, 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Loss Before Income Taxes</h4><p>Loss before income taxes was -$11,991,963 for the fiscal year ended December 31, 2025, an increase from -$11,044,012 in the prior fiscal year <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Net Loss Attributable to Shareholders</h4><p>The net loss attributable to shareholders of MediciNova, Inc. was -$11,997,957 for the fiscal year ended December 31, 2025, compared to -$11,049,549 for the fiscal year ended December 31, 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Comprehensive Loss</h4><p>Comprehensive loss for the fiscal year ended December 31, 2025, was -$11,989,983, increasing from -$11,066,613 in the previous fiscal year <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Total Assets</h4><p>Total assets decreased to $45,603,109 as of December 31, 2025, from $55,875,926 as of December 31, 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Total Equity (Net Assets)</h4><p>Total equity (net assets) decreased to $41,586,681 as of December 31, 2025, from $52,503,551 as of December 31, 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Shareholders’ Equity Ratio</h4><p>The shareholders’ equity ratio was 91.2% as of December 31, 2025, a decrease from 94.0% as of December 31, 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Cash and Cash Equivalents</h4><p>Cash and cash equivalents at the end of the period were $30,806,477 as of December 31, 2025, down from $40,359,738 as of December 31, 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Cash Flows from Operating Activities</h4><p>Net cash used in operating activities was -$9,810,061 for the fiscal year ended December 31, 2025, an improvement from -$10,642,964 in the prior fiscal year <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Cash Flows from Investing Activities</h4><p>Net cash used in investing activities was -$2,899 for the fiscal year ended December 31, 2025, compared to -$697 for the fiscal year ended December 31, 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Cash Flows from Financing Activities</h4><p>Net cash provided by financing activities was $244,018 for the fiscal year ended December 31, 2025, primarily from the issuance of equity under a standby equity purchase agreement (SEPA), with no cash provided by financing activities in the prior fiscal year <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Cost of Services</h4><p>Cost of services was $378,606 for the fiscal year ended December 31, 2025, with no cost of services recorded in the prior fiscal year <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Research, Development and Patents Expenses</h4><p>Research, development and patents expenses were $7,154,848 for the fiscal year ended December 31, 2025, which was generally at the same level as $7,194,731 in the prior fiscal year <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>General and Administrative Expenses</h4><p>General and administrative expenses increased by $0.7 million to $6,159,205 for the fiscal year ended December 31, 2025, from $5,480,600 in the prior fiscal year, primarily due to SEPA fees and increased professional and investor relations expenses <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Interest Income</h4><p>Interest income decreased by $0.4 million to $1,303,792 for the fiscal year ended December 31, 2025, from $1,670,804 in the prior fiscal year, mainly due to a decrease in the cash balance <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p><h4>Outlook / Guidance for Fiscal Year Ending December 31, 2026</h4><p>MediciNova, Inc. plans to continue focusing its resources on the clinical development of MN-166 and MN-001, expecting research and development expenses to increase <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>. The company anticipates operating expenses of approximately $16.2 million, an 18% increase compared to 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>. However, MediciNova, Inc. has not provided specific consolidated forecast figures for revenues and operating income due to ongoing strategic collaborations and out-licensing activities <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1226616/000119312526060232/d101814dex991.htm"></span>.</p>

Medicinova | 8-K: FY2025 Revenue: USD 409.66 K